GH releasing peptides (GHRPs) were developed before the isolation and
identification of GH releasing hormone (GHRH) in 1982 yet the clinical
era of the GHRPs began in 1988. Since then clinical studies have been
greatly extended. We studied the effects of GHRPs on GH release as a
function of age, metabolic status and in different neuroendocrine path
ologies, The different mechanism of action of GHRPs versus GHRH and th
e site of action have been addressed. There is a large variability in
the stimulatory action of GHRH contrasted with the reproducibility of
action of GHRPs. In different metabolic states GH response after GHRH
is more impaired than after GHRP-6. On the other hand in different neu
roendocrine pathologies GH response after GHRP-6 is more impaired than
after GHRH. Each secretagogue provides separate information on GH sec
retion, necessary not only for linear growth but for general metabolis
m.